Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on beta-blockers

Introduction: The efficacy and safety of a new once-daily (QD) fixed-dose combination (FDC) with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting ß2-agonist, was established for the treatment of COPD in the TONADO studies1. This analysis evaluates the efficacy of the FDC in a subpopulation of patients receiving ß-blockers (BBs) in these studies. Methods: Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O FDC (2.5/5 µg; 5/5 µg; Respimat® inhaler) QD compared to the monocomponents. Key primary end point da…